Pharmaceutical Industrial Policy Committee Study Group on Extending Healthy Life Expectancy and Driving Economic Growth ～Research and Proposal on the Contribution of the Pharmaceutical Industry to Extending Healthy Life Expectancy and Driving Economic Growth
Reports
Data in Charts 5 and 6 of the report published on 4/20 were incorrect. The data has now been corrected in the published version. We apologize for any inconvenience caused.
Overview
We are pleased to announce the establishment of the "Study Group on Extending Healthy Life Expectancy and Driving Economic Growth - Toward the Future of the Pharmaceutical Industry" (hereinafter referred to as the "Study Group").
There is a mountain of social issues related to "health" and "economy." In particular, in the medical field, there are various issues such as the medical care delivery system due to the declining population and future financial concerns in response to the increasing demand for medical care due to the aging of the population.
We invite experts who are leading academic research on the state of healthcare as a whole to participate in this study group and discuss from an "objective" and "neutral" standpoint how the pharmaceutical industry can contribute to resolving these issues, as well as to widely communicate what the pharmaceutical industry should aim for based on the evidence obtained through evaluation and analysis. We also hope that the pharmaceutical industry will widely communicate its vision of what it should aim for based on the evidence it has evaluated and analyzed.
The Japan Pharmaceutical Manufacturers Association (JPMA, Chairman: Yasushi Okada) will do its utmost to support the discussions in the Study Group, and will publicize the evidence and other information provided by the Study Group on its website.
For further information, please contact
JPMA Secretariat, Policy Division